 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...224225226227228229230231232233234...235236» |
- Stivarga (regorafenib) / Bayer
Enrollment change, Metastases: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines (clinicaltrials.gov) - Mar 11, 2013
P3, N=0, Withdrawn, Sponsor: Asan Medical Center
N=224 --> 0
- ||| Cyramza (ramucirumab) / Eli Lilly, icrucumab (IMC-18F1) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: A Study of Ramucirumab or Icrucumab in Colorectal Cancer (clinicaltrials.gov) - Mar 10, 2013
P2, N=156, Active, not recruiting, Sponsor: ImClone LLC
N=224 --> 0 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial initiation date, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Mar 4, 2013
P2, N=256, Recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting Initiation date: Nov 2010 --> Feb 2011
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment change, Surgery: Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE) (clinicaltrials.gov) - Mar 3, 2013
P2, N=63, Completed, Sponsor: University Hospital, Rouen
Initiation date: Nov 2010 --> Feb 2011 N=42 --> 63
- saridegib oral (IPI 926 oral) / Infinity Pharma
Enrollment closed, Metastases: FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 3, 2013
P1, N=21, Active, not recruiting, Sponsor: Andrew Ko
N=42 --> 63 Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Mar 3, 2013
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Surgery: Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE) (clinicaltrials.gov) - Mar 3, 2013
P2, N=63, Completed, Sponsor: University Hospital, Rouen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial termination, Metastases: FOSCO: Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer (clinicaltrials.gov) - Feb 28, 2013
P2, N=101, Terminated, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- Enrollment change, Metastases: FOSCO: Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer (clinicaltrials.gov) - Feb 28, 2013
P2, N=101, Terminated, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Terminated N=240 --> 101
- ||| andecaliximab (GS-5745) / Gilead
New P1 trial, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 28, 2013
P1, N=104, Recruiting, Sponsor: Gilead Sciences
- | leucovorin calcium / Generic mfg.
New P2 trial, Metastases: VELVET: OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 27, 2013
P2, N=49, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial: CELIM2: Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases (clinicaltrials.gov) - Feb 27, 2013
P2, N=256, Recruiting, Sponsor: Technische Universit
- Avastin (bevacizumab) / Roche
Enrollment closed, Surgery, Metastases: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 26, 2013
P2, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
N=240 --> 101 Recruiting --> Active, not recruiting
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial termination: Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer (clinicaltrials.gov) - Feb 25, 2013
P3, N=3000, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- ||| duligotuzumab (MEHD7945A) / Roche
Trial initiation date, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 25, 2013
P2, N=135, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Terminated Initiation date: Jul 2012 --> Oct 2012
- irinotecan / Generic mfg.
Enrollment change, Metastases: Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Feb 25, 2013
P2, N=500, Active, not recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Initiation date: Jul 2012 --> Oct 2012 N=50 --> 500
- |||| Erbitux (cetuximab) / Eli Lilly
Enrollment open, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - Feb 24, 2013
P2, N=375, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
N=50 --> 500 Suspended --> Recruiting
- | Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer (clinicaltrials.gov) - Feb 24, 2013
P2, N=35, Active, not recruiting, Sponsor: Yale University
Suspended --> Recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2013
P2, N=25, Recruiting, Sponsor: Drexel University
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | pentamidine oral (VLX103) / Odan Labs
Enrollment closed, Metastases: Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (clinicaltrials.gov) - Feb 19, 2013
P2, N=48, Active, not recruiting, Sponsor: Oncozyme Pharma Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Avastin (bevacizumab) / Roche
Trial initiation date, Metastases: ML18147: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Feb 18, 2013
P3, N=821, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Nov 2005 --> Feb 2006
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed: PLANET: Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (clinicaltrials.gov) - Feb 18, 2013
P2, N=80, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Initiation date: Nov 2005 --> Feb 2006 Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial initiation date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 17, 2013
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Initiation date: Sep 2012 --> Feb 2013
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., arsenic trioxide / Generic mfg.
Enrollment change, Metastases: Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment (clinicaltrials.gov) - Feb 17, 2013
P1, N=13, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Initiation date: Sep 2012 --> Feb 2013 N=20 --> 13
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 17, 2013
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
N=20 --> 13 Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., arsenic trioxide / Generic mfg.
Trial completion, Metastases: Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment (clinicaltrials.gov) - Feb 17, 2013
P1, N=13, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting --> Recruiting Suspended --> Completed
- buparlisib (AN2025) / Adlai Nortye
Enrollment open, Metastases: BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (clinicaltrials.gov) - Feb 14, 2013
P1, N=60, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Suspended --> Completed Not yet recruiting --> Recruiting
- | conatumumab (AMG 655) / Amgen
Enrollment change: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting N=30 --> 12
- Avastin (bevacizumab) / Roche
Clinical: ORCHESTRA: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=478, Recruiting, Sponsor: VU University Medical Center
- | conatumumab (AMG 655) / Amgen
Enrollment open: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
N=30 --> 12 Active, not recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial termination: Neo-Adjuvant FOLFOX for Rectal Carcinoma (clinicaltrials.gov) - Feb 12, 2013
P2, N=2, Terminated, Sponsor: Beth Israel Medical Center
Active, not recruiting --> Recruiting Recruiting --> Terminated; terminated for lack of enrollment
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change: Neo-Adjuvant FOLFOX for Rectal Carcinoma (clinicaltrials.gov) - Feb 12, 2013
P2, N=2, Terminated, Sponsor: Beth Israel Medical Center
Recruiting --> Terminated; terminated for lack of enrollment N=22 --> 2
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer (clinicaltrials.gov) - Feb 11, 2013
P2, N=16, Terminated, Sponsor: Hellenic Oncology Research Group
N=22 --> 2 N=50 --> 16
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Metastases: Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC (clinicaltrials.gov) - Feb 9, 2013
P3, N=390, Active, not recruiting, Sponsor: Alchemia Oncology
N=50 --> 16 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
New P1/2 trial: LeMLAR: Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas (clinicaltrials.gov) - Feb 7, 2013
P1/2, N=44, Recruiting, Sponsor: University Hospital, Essen
- Stivarga (regorafenib) / Bayer
New P3 trial, Metastases: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines (clinicaltrials.gov) - Feb 6, 2013
P3, N=0, Withdrawn, Sponsor: Asan Medical Center
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Metastases: FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=64, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Surgery, Metastases: ADORE: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer (clinicaltrials.gov) - Feb 2, 2013
P2, N=320, Active, not recruiting, Sponsor: Asan Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Enrollment change, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 31, 2013
P1, N=33, Active, not recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting N=60 --> 33
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Combination therapy, Metastases: Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 31, 2013
P2, N=36, Completed, Sponsor: SCRI Development Innovations, LLC
N=60 --> 33 N=70 --> 36
- Enrollment change, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jan 31, 2013
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=70 --> 36 N=78 --> 38
- ||| AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Jan 31, 2013
P1, N=60, Recruiting, Sponsor: Bristol-Myers Squibb
N=78 --> 38 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Enrollment closed, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 31, 2013
P1, N=33, Active, not recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Biomarker, Enrollment closed: Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jan 31, 2013
P1, N=76, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jan 31, 2013
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial (clinicaltrials.gov) - Jan 30, 2013
P3, N=16, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 30, 2013
P2, N=156, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial termination, Metastases: Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (clinicaltrials.gov) - Jan 28, 2013
P4, N=51, Terminated, Sponsor: Myriad Genetic Laboratories, Inc.
Active, not recruiting --> Completed Recruiting --> Terminated; Study terminated due to slow enrollment.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Metastases: Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (clinicaltrials.gov) - Jan 28, 2013
P4, N=51, Terminated, Sponsor: Myriad Genetic Laboratories, Inc.
Recruiting --> Terminated; Study terminated due to slow enrollment. N=549 --> 51
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors (clinicaltrials.gov) - Jan 28, 2013
P1, N=54, Completed, Sponsor: National Cancer Institute (NCI)
N=549 --> 51 N=70 --> 54